Progesterone and Glucocorticoid Receptor Modulator Mifepristone (RU-486) as Treatment for Advanced Cancers
The fetal placental unit has paternal proteins which would normally result in immune rejection of fetus. Thus, to allow growth to 266 days, the mother must develop immunosuppressive proteins, cytokines, etc. to allow progression to a full-term baby. One of these essential immunomodulatory proteins i...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2020
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/73134 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Progesterone and Glucocorticoid Receptor Modulator Mifepristone (RU-486) as Treatment for Advanced Cancers
- Progesterone Resistance and Targeting the Progesterone Receptors: A Therapeutic Approach to Endometriosis
- Minimal and Natural Stimulations for IVF
- The Glucocorticoid Receptor in Retroviral Infection
- Regulation of Glucocorticoid Receptor Signaling and the Diabetogenic Effects of Glucocorticoid Excess
- Telocytes in Human Fallopian Tube and Uterus Express Estrogen and Progesterone Receptors
- Role of Glucocorticoid Receptor in the Relation between Stress and Opiate Addiction